7427 Stock Overview
Engages in the development of drugs for the treatment of advanced and refractory cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Great Novel Therapeutics Biotech & Medicals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$36.70 |
| 52 Week High | NT$78.00 |
| 52 Week Low | NT$32.05 |
| Beta | -0.014 |
| 11 Month Change | -5.78% |
| 3 Month Change | -3.80% |
| 1 Year Change | -51.90% |
| 33 Year Change | 2.80% |
| 5 Year Change | n/a |
| Change since IPO | -43.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7427 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -0.8% | -3.1% | -0.8% |
| 1Y | -51.9% | 2.0% | 29.0% |
Return vs Industry: 7427 underperformed the TW Biotechs industry which returned 2% over the past year.
Return vs Market: 7427 underperformed the TW Market which returned 29% over the past year.
Price Volatility
| 7427 volatility | |
|---|---|
| 7427 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 7427's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 7427's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 19 | Chia-Nan Chen | www.gntbm.com.tw |
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. It develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation.
Great Novel Therapeutics Biotech & Medicals Fundamentals Summary
| 7427 fundamental statistics | |
|---|---|
| Market cap | NT$1.60b |
| Earnings (TTM) | -NT$87.43m |
| Revenue (TTM) | NT$615.00k |
2,601x
P/S Ratio-18.3x
P/E RatioIs 7427 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7427 income statement (TTM) | |
|---|---|
| Revenue | NT$615.00k |
| Cost of Revenue | NT$243.00k |
| Gross Profit | NT$372.00k |
| Other Expenses | NT$87.80m |
| Earnings | -NT$87.43m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.01 |
| Gross Margin | 60.49% |
| Net Profit Margin | -14,216.10% |
| Debt/Equity Ratio | 0% |
How did 7427 perform over the long term?
See historical performance and comparison